Aquestive Therapeutics reports Q1 EPS (17c), consensus (8c)

Reports Q1 revenue $12.1M, consensus $12.26M. Cash and cash equivalents were $95.2M as of March 31. “We continue to successfully execute on our growth strategy as demonstrated by our first quarter results,” said Daniel Barber, CEO of Aquestive. “Over the last several quarters, we have reduced our cash burn, refinanced our debt, significantly strengthened our cash position, attracted high quality institutional healthcare investors, successfully completed our Anaphylm Phase 3 study, and received FDA approval for Libervant in patients between ages 2 to 5. We are focused on continuing our successful track record by executing on the remaining Anaphylm pre-submission studies, developing the commercial infrastructure to support Anaphylm, and efficiently launching Libervant. This approval of Libervant, our fourth FDA approval since 2018, exemplifies our approach to collaborating with the FDA and we plan to continue this with the filing of our Anaphylm application.”